The present invention is directed virus-like particles (VLPs) which are useful in immunogenic compositions and vaccines epitopes mediating protection are disclosed. Immunogenic peptides are identified and are displayed on virus-like particles, especially Qbeta, MS2, or AP205 VLPs which provide a potent immunogenic response in a patient or subject and enhanced protection from Ct infection in a patient or subject. Pharmaceutical compositions and vaccines are disclosed as are methods for providing an immunogenic response and/or vaccinating a patient or subject against Chlamydia trachomatis infections.

The present invention is directed virus-like particles (VLPs) which are useful in immunogenic compositions and vaccines epitopes mediating protection are disclosed. Immunogenic peptides are identified and are displayed on virus-like particles, especially Qbeta, MS2, or AP205 VLPs which provide a potent immunogenic response in a patient or subject and enhanced protection from Ct infection in a patient or subject. Pharmaceutical compositions and vaccines are disclosed as are methods for providing an immunogenic response and/or vaccinating a patient or subject against Chlamydia trachomatis infections.

Disclosed herein, are compositions and methods using Chlamydia muridarum organisms in the treatment and prevention of human Chlamydia trachomatis infections in a subject. Also, disclosed herein are compositions and methods for eliciting an immune response in a subject and for use as vectors.

Disclosed herein, are compositions and methods using Chlamydia muridarum organisms in the treatment and prevention of human Chlamydia trachomatis infections in a subject. Also, disclosed herein are compositions and methods for eliciting an immune response in a subject and for use as vectors.

Disclosed herein are methods and platforms for increasing utility and efficacy of a cellular vaccine. Specifically, disclosed are steps that optimize ex vivo B cell expansion and boost host in vivo immunity. Also disclosed is a platform for enhancing effectiveness of antigen presentation and antigen-specific immune responses. Also disclosed is a method for enhancing effectiveness of APCs in a subject. Also disclosed are vaccines and kits based on the platform.

Disclosed herein are methods and platforms for increasing utility and efficacy of a cellular vaccine. Specifically, disclosed are steps that optimize ex vivo B cell expansion and boost host in vivo immunity. Also disclosed is a platform for enhancing effectiveness of antigen presentation and antigen-specific immune responses. Also disclosed is a method for enhancing effectiveness of APCs in a subject. Also disclosed are vaccines and kits based on the platform.

Disclosed are compositions, kits, and methods for enhancing growth in an animal in need thereof. The methods typically comprise administering orally to the animal a composition comprising biodegradable particles, the biodegradable particles comprising a polymer or a co-polymer comprising polymerized lactic acid and having an effective average diameter of 0.5-5 m. In the methods, the animal is administered a dose of the biodegradable particles that is effective for improving feed conversion rate in the animal in comparison to an animal that is not administered the composition.

Disclosed are compositions, kits, and methods for enhancing growth in an animal in need thereof. The methods typically comprise administering orally to the animal a composition comprising biodegradable particles, the biodegradable particles comprising a polymer or a co-polymer comprising polymerized lactic acid and having an effective average diameter of 0.5-5 m. In the methods, the animal is administered a dose of the biodegradable particles that is effective for improving feed conversion rate in the animal in comparison to an animal that is not administered the composition.

The invention discloses a method for the formation of liposomes by using high shear mixing of aqueous solution of lipid powder; the lipid powder can be produced by any known technique. Components of the liposomes include but are not limited to cationic lipids, immunostimulators/immunopotentiators and macromolecules as components for the liposome formation. The disclosed method describes the formulation of stable liposomes solitary or complexing high concentrations of macromolecules such as proteins, DNA and RNA having opposite charge of the liposomes by high shear mixing where aggregation is avoided due to the formulation method.

The invention discloses a method for the formation of liposomes by using high shear mixing of aqueous solution of lipid powder; the lipid powder can be produced by any known technique. Components of the liposomes include but are not limited to cationic lipids, immunostimulators/immunopotentiators and macromolecules as components for the liposome formation. The disclosed method describes the formulation of stable liposomes solitary or complexing high concentrations of macromolecules such as proteins, DNA and RNA having opposite charge of the liposomes by high shear mixing where aggregation is avoided due to the formulation method.